Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-24. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For the lyophilised powder, desiccated |
| Storage form | Sealed vial, protected from light | Amber glass or foil-wrapped containers |
| Reconstituted stability | Short, refrigerate | Degradation accelerates in solution |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity assessment plus identity confirmation |
| Common synonyms | Melanotan II, MT-II | Also written melanotan-2 |
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
To date it is still under debate whether the base complex assembles separately, whether the assembly is templated by the 20S core particle, or whether alternative assembly pathways exist. In addition to the four assembly chaperones, the deubiquitinating enzyme Ubp6/Usp14 also promotes base assembly, but it is not essential. The lid assembles separately in a specific order and does not require assembly chaperones.
In addition to tracks from all of their studio albums, the box set contains live tracks dating back to 1974 through the band's final show in 2015, and also marked the first time that their 1973 debut single "Not Fade Away" and its B-side "You Can't Fight It" were made available on any other format. Upon the release of Rush 50, concerns emerged over the authenticity and artistic value of the artwork, as Rush fans widely speculated art director Hugh Syme may have created the Rush 50 artwork using generative artificial intelligence tools.
Maple syrup urine disease (MSUD) is a rare, inherited metabolic disorder that affects the body's ability to metabolize amino acids due to a deficiency in the activity of the branched-chain alpha-ketoacid dehydrogenase (BCKAD) complex. It particularly affects the metabolism of amino acids leucine, isoleucine, and valine. With MSUD, the body is not able to properly break down these amino acids, therefore leading to the amino acids to build up in urine and become toxic. The condition gets its name from the distinctive sweet odor of affected infants' urine and earwax due to the buildup of these amino acids.
The European Monitoring Centre for Drugs and Drug Addiction's latest systematic review from April 2010 did not find any evidence to support concerns that DCR might "encourage drug use, delay treatment entry or aggravate problems of local drug markets." Jürgen Rehm and Benedikt Fischer explained that while evidence show that DCR are successful, that "interpretation is limited by the weak designs applied in many evaluations, often represented by the lack of adequate control groups." Concluding that this "leaves the door open for alternative interpretations of data produced and subsequent ideological debate." The EMCDDA review noted that research into the effects of the facilities "faces methodological challenges in taking account of the effects of broader local policy or ecological changes", still they concluded "that the facilities reach their target population and provide immediate improvements through better hygiene and safety conditions for injectors." Further that "the availability of safer injecting facilities does not increase levels of drug use or risky patterns of consumption, nor does it result in higher rates of local drug acquisition crime." While its usage is "associated with self-reported reductions in injecting risk behaviour such as syringe sharing, and in public drug use" and "with increased uptake of detoxification and treatment services." However, "a lack of studies, as well as methodological problems such as isolating the effect from other interventions or low coverage of the risk population, evidence regarding DCRs—while encouraging—is insufficient for drawing conclusions with regard to their effectiveness in reducing HIV or hepatitis C virus (HCV) incidence." Concluding with that "there is suggestive evidence from modelling studies that they may contribute to reducing drug-related deaths at a city level where coverage is adequate, the review-level evidence of this effect is still insufficient." Critics of this intervention, such as drug prevention advocacy organisations, Drug Free Australia and Real Women of Canada point to the most rigorous evaluations, those of Sydney and Vancouver. Two of the centers, in Sydney, Australia and Vancouver, British Columbia, Canada cost $2.7 million and $3 million per annum to operate respectively, yet Canadian mathematical modeling, where there was caution about validity, indicated just one life saved from fatal overdose per annum for Vancouver, while the Drug Free Australia analysis demonstrates the Sydney facility statistically takes more than a year to save one life. The Expert Advisory Committee of the Canadian Government studied claims by journal studies for reduced HIV transmission by Insite but "were not convinced that these assumptions were entirely valid." The Sydney facility showed no improvement in public injecting and discarded needles beyond improvements caused by a coinciding heroin drought, while the Vancouver facility had an observable impact. Drug dealing and loitering around the facilities were evident in the Sydney evaluation, but not evident for the Vancouver facility.
== In bacteria == All bacteria use proteolipids, sometimes confusingly referred to as bacterial lipoproteins, in their cell membrane. A common modification consists of N-acyl- and S‑diacylglycerol attached to an N-terminal cystine residue. Braun's lipoprotein, found in gram-negative bacteria, is a representative of this group. In addition, Mycobacterium O-mycolate proteins destined for the outer membrane. The plant chloroplast is capable of many of the same modifications that bacteria perform to proteolipids. One database for such N-Acyl Diacyl Glycerylated cell wall proteolipids is DOLOP. Pathogenic spirochetes, including Borrelia burgdorferi and Treponema pallidum, use their proteolipid adhesins to stick to victim cells. These proteins are also potent antigens, and are in fact the main immunogens of these two species. Proteolipids include bacterial antibiotics that are not synthesised in the ribosome. Products of nonribosomal peptide synthase may also involve a peptide structure linked to lipids. These are usually referred to as "lipopeptides". Bacterial "lipoproteins" and "lipopeptides" (LP) are potent inducers of sepsis, second only to lipopolysaccharide (LPS) in its ability to cause an inflammation response. While LPS is detected by the toll-like receptor TLR4, LPs are detected by TLR2.
Sources: en.wikipedia.org
isomerase Any of a class of enzymes which catalyze the conversion of a molecule from one isomer to another, such that the product of the reaction has the same molecular formula as the original substrate but differs in the connectivity or spatial arrangement of its atoms.
Secondary structure prediction is a set of techniques in bioinformatics that aim to predict the local secondary structures of proteins based only on knowledge of their amino acid sequence. For proteins, a prediction consists of assigning regions of the amino acid sequence as likely alpha helices, beta strands (often termed extended conformations), or turns. The success of a prediction is determined by comparing it to the results of the DSSP algorithm (or similar e.g. STRIDE) applied to the crystal structure of the protein. Specialized algorithms have been developed for the detection of specific well-defined patterns such as transmembrane helices and coiled coils in proteins. The best modern methods of secondary structure prediction in proteins were claimed to reach 80% accuracy after using machine learning and sequence alignments; this high accuracy allows the use of the predictions as feature improving fold recognition and ab initio protein structure prediction, classification of structural motifs, and refinement of sequence alignments. The accuracy of current protein secondary structure prediction methods is assessed in weekly benchmarks such as LiveBench and EVA.
More New York City Police Department (NYPD) officers were added, and District Attorney Robert Morgenthau agreed to process arrests in Bryant Park more quickly. By 1978, public perception of Bryant Park's safety was slightly better than in previous years, though drug dealers still frequented the park after office workers had gone back to work following their lunch breaks. Furthermore, NYPD officers initially declined to arrest drug users who were nonviolent. Starting in 1979, a coordinated program of amenities, including book and flower markets, landscape improvements, and entertainment activities, was initiated by a parks advocacy group called the Parks Council. Though the Parks Council's activities became popular, drug use and small crimes were still common within the park through the early 1980s. After a group of undercover NYPD officers were stationed in the park starting in 1980, they had made 400 drug-related arrests within six months.
Pierre, et de Beatrix de Guine (1738 - English translation: Stories of the Earl of Oxford, of Milady of Herby, of Eustace of St. Peter, and of Beatrix of Guinea) La jeune Alcidiane (1733 - English translation: The Young Alcidiane) Les journées amusantes, dédiées au roi (1722 - English translation by Eliza Haywood: La Belle Assemblée published 1724–1734)
The shot is a liquid volume measure that varies from country to country and state to state depending on legislation. It is routinely used for measuring strong liquor or spirits when the amount served and consumed is smaller than the more common measures of alcoholic "drink" and "pint". There is a legally defined maximum size of a serving in some jurisdictions. The size of a "single" shot is 20–60 ml (0.70–2.11 imp fl oz; 0.68–2.03 US fl oz). The smaller "pony" shot is 20–30 ml (0.70–1.06 imp fl oz; 0.68–1.01 US fl oz). According to Encyclopædia Britannica Almanac 2009, a pony is 0.75 fluid ounces of liquor. According to Wolfram Alpha, one pony is 1 U.S. fluid ounce. "Double" shots (surprisingly not always the size of two single shots, even in the same place) are 40–100 ml (1.4–3.5 imp fl oz; 1.4–3.4 US fl oz). In the UK, spirits are sold in shots of either 25 ml (0.88 imp fl oz; 0.85 US fl oz) (approximating the old fluid ounce) or 35 ml (1.2 imp fl oz; 1.2 US fl oz).
Sources: en.wikipedia.org
The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.
Reversed-phase liquid chromatography assesses purity, while mass spectrometry confirms molecular mass and detects sequence errors. Amino acid analysis and peptide mapping add structural detail. These techniques are complementary rather than interchangeable.
It is listed as a prohibited peptide hormone by the World Anti-Doping Agency. No medicines regulator has approved it for human use. Import and sale rules vary by country.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.